Why the study?
The role of high on-treatment platelet reactivity in predicting recurrent vascular events after cerebrovascular incidents, particularly regarding stroke etiology, was not established.
Does high on-treatment platelet reactivity (aspirin resistance) increase the risk of recurrent vascular events in patients with non-embolic cerebral ischemia treated with aspirin?
Population
101 subjects with non-embolic cerebral ischemia (69 ischemic stroke, 32 TIA) treated with aspirin 150 mg daily
Comparison
High on-treatment platelet reactivity (HTPR) vs normal on-treatment platelet reactivity (NTPR)
Design
Prospective cohort study
Follow-up
36 months
Authors
Loading...
Should not yet change antiplatelet selection after non-embolic stroke or TIA; leaves open HTPR-guided therapy, especially in large-vessel disease.
Does high on-treatment platelet reactivity (aspirin resistance) increase the risk of recurrent vascular events in patients with non-embolic cerebral ischemia treated with aspirin?
Aspirin resistance in the acute phase of cerebral ischemia is associated with a significantly higher risk of recurrent medium-term vascular events, particularly in patients with large-vessel disease.
Wiśniewski et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: